Get Even More Visitors To Your Blog, Upgrade To A Business Listing >>

Vitae Pharmaceuticals Inc (VTAE) Profit Expected to Decrease

The institutional sentiment decreased to 1.8 in Q2 2015. Its down 1.13, from 2.93 in 2015Q1. The ratio fall, as 12 funds sold all Vitae Pharmaceuticals Inc shares owned while 8 reduced positions. 14 funds bought stakes while 22 increased positions. They now own 13.29 million shares or 13.23% more from 11.74 million shares in 2015Q1.

Bvf Inc Il holds 4.08% of its portfolio in Vitae Pharmaceuticals Inc for 1.60 million shares. Nea Management Company Llc owns 2.61 million shares or 1.97% of their US portfolio. Moreover, Awm Investment Company Inc. has 1.78% invested in the company for 872,000 shares. The New York-based Ghost Tree Capital Llc has invested 1.44% in the stock. Perceptive Advisors Llc, a New York-based fund reported 150,000 shares.

Vitae Pharmaceuticals, Inc. is a biotechnology company. The company has a market cap of $178.05 million. The Firm is focused on discovering and developing small molecule drugs for diseases. It currently has negative earnings. It is engaged in developing a portfolio of product candidates through Contour, its structure drug discovery platform.

The post Vitae Pharmaceuticals Inc (VTAE) Profit Expected to Decrease appeared first on Octafinance.



This post first appeared on Octafinance – Financial News, Reports And Intell, please read the originial post: here

Share the post

Vitae Pharmaceuticals Inc (VTAE) Profit Expected to Decrease

×

Subscribe to Octafinance – Financial News, Reports And Intell

Get updates delivered right to your inbox!

Thank you for your subscription

×